Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acarbose chewable tablets added to insulin with or without metformin in type 2 diabetes with inadequate insulin control
ChiCTR2000031284Phase 4Recruiting
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Start
- Apr 2019
- Modality
- Microbiome-Derived Products → Microbiome Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of acarbose in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by The First Affiliated Hospital of Zhengzhou University. Primary endpoints: HbA1c and Blood glucose fluctuation. Started Apr 2019; status: recruiting.
02
Drugs
acarbose
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ChiCTR2000031284.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000031284.